• A project of ASAPbio
    • About
    • Add listing
    • Glossary
    • Blog
    Explore
    Sign in or Register
    Explore

    Sinai Immunology Review Project

    Reviewing COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

    • Share
    • Bookmark
    • Profile
    • Comments 0
    • prev
    • next
    • Website
    • Leave a comment
    • prev
    • next
    In a nutshell

    This repo contains reviews for COVID-19 preprints written by Sinai immunlogists (see https://twitter.com/SinaiImmunol). The reviews are under an open license and are being pulled into the Observable notebook https://observablehq.com/@ismms-himc/covid-19-sars-cov-2-preprints-from-medrxiv-and-biorxiv for easy browsing.

    Goals and intentions

    We initiated an institutional effort to provide critical reviews of COVID-19 articles posted daily on the preprint servers bioRxiv and medRxiv1, which we call the Sinai Immunology Review Project. This effort was designed to meet two needs. The first is a desire from our students, postdocs, fellows and faculty members to contribute to the global research effort and harness their knowledge and skills to help the scientific community. The second stems from a challenging consequence of the growing importance of preprints in scientific communication. The swift and open dissemination of information offered by preprints has already proved crucial in providing rapid scientific responses to the emerging public threat of viral outbreaks. However, the ambition of preprint servers was never to replace the peer-review process. The spread of the COVID-19 pandemic has been matched by an impressive rise in related publications in both preprint servers and peer-reviewed journals. At a time when journal editors and invited reviewers are more solicited than ever, we decided that it is the responsibility of the scientific community to help curate this unprecedented flow of scientific data. Reviewing preprints benefits both the authors and the scientific community and provides the general public with access to scientific discussion, helping to reinforce scientific credibility.

    Project status
    • Active
    Types of outputs
    • Preprints
    Review process
    • Review requested by
      Non-authors
    • Reviewer selected by
      Self-nominated
    • Public interaction
      Yes
    • Author response
      No
    • Decision
      None
    Review policy
    • Review coverage
      Complete paper
    • Reviewer identity known to
      Editor or service, Public
    • Competing interests
      Not included
    Social Networks
    • Twitter
    Gallery
    Review features
    • Manuscript hosting
      No
    • Notes

      Our workflow ranks each COVID-19-related preprint (totalling 1,772 to date) according to its immunological relevance. The most relevant papers are then reviewed in detail by trainees and validated by a faculty member. Validated reviews (118 to date) are then posted alongside the corresponding article on the preprint server. A PrIISM scientist, Nicolas Fernandez, built a dedicated website to host and integrate all of our reviews (see Related links), which are further shared with other pre-publication reviewing initiatives. We have also launched a collaboration with Nature Reviews Immunology to publish short summaries of preprints of particular interest in a weekly column.

    • Review of code or data
      No
    • Eligible reviewers/editors
      Immunologists at Mount Sinai New York
    • Tags or badges
      Yes
    • Criteria for inclusion

      COVID-19 reprints posted on bioRxiv and medRxiv.

    Transparency
    • Open identities
    • Open reports
    Results
    • Number of scholarly outputs commented on
      100-1,000
    mood_bad
  • No comments yet.
  • Add a comment

    Leave a Reply · Cancel reply

    Your email address will not be published. Required fields are marked *

    Partners

    ReimagineReview is a project of ASAPbio funded by CZI and developed in partnership with Wellcome and the Howard Hughes Medical Institute.

      

    License

    Except where otherwise noted, text on this site is licensed under a Creative Commons Attribution 4.0 International license by ASAPbio. Listing data (text and multiple-choice responses) are released under the CC0 public domain waiver. All project and service logos, images, videos, and brands are property of their respective owners and should not be reused without permission, except where otherwise noted.

    Cart

      • Facebook
      • Twitter
      • WhatsApp
      • Telegram
      • LinkedIn
      • Tumblr
      • VKontakte
      • Mail
      • Copy link